Table 1.

Patient characteristics

Variable	Entire cohort (N = 802)	MAC (n =321; 40%)	RIC (n = 481; 60%)	P
Age at HCT, median, y	59.58 (range, 18.58-78.64; IQR, 52.49-65.05)	54.29 (range, 18.58-74.51; IQR, 45.48-61.14)	61.98 (range, 19.96-78.64; IQR, 56.72-66.43)	<.0001
Time to HCT, median, mo	4.47 (range, 0.23-137.73; IQR, 3.09-6.69)	4.37 (range, 0.26-108.83; IQR, 2.79-6.7)	4.6 (range, 0.23-137.73; IQR, 3.19-6.67)	.2669
Engraftment	741 (95.2)	297 (94.6)	444 (95.7)	.5906
Time to engraftment, median, d	17 (range, 3-89; IQR, 14-20)	17 (range, 3-89; IQR, 13.5-20)	17 (range, 4-77; IQR, 14-20)	.8290
Source of stem cells (peripheral blood)	722 (90.1)	274 (85.4)	448 (93.3)	.0003
Disease status				.1045
Advanced	364 (45.4)	152 (47.4)	212 (44.1)
CR1	396 (49.4)	147 (45.8)	249 (51.8)
CR1	42 (5.2)	22 (6.9)	20 (4.2)
KPS*				.1088
Poor (<80%)	66 (9)	20 (6.7)	46 (10.5)
Good (≥80%)	671 (91)	277 (93.3)	394 (89.5)
Donor HLA				.1358
MSD	340 (42.4)	141 (43.9)	199 (41.4)
URD 10/10	370 (46.1)	152 (47.4)	218 (45.3)
URD 9/10	92 (11.5)	28 (8.7)	64 (13.3)
Donor to patient sex				.0251
Female to male	166 (20.9)	53 (16.8)	113 (23.6)
Other	628 (79.1)	263 (83.2)	365 (76.4)
Cytogenetic risk				.0339
Intermediate	538 (67.1)	201 (62.6)	337 (70.1)
Poor	264 (32.9)	120 (37.4)	144 (29.9)
T-cell depletion				<.0001
No TCD	263 (32.8)	138 (43)	125 (26)
ATG/Campath	539 (67.2)	183 (57)	356 (74)
Use of TBI				.0008
Yes	624 (77.8)	230 (71.7)	394 (81.9)
No	178 (22.2)	91 (28.3)	87 (18.1)
CMV status (patient)				.2589
Negative	248 (31.9)	90 (29.4)	158 (33.5)
Positive	529 (68.1)	216 (70.6)	313 (66.5)
CMV status (donor)				.9626
Negative	383 (49.3)	151 (49)	232 (49.5)
Positive	394 (50.7)	157 (51)	237 (50.5)

Values are n (%) unless otherwise noted.

ATG, antithymocyte globulin; CMV, cytomegalovirus; CR, complete remission; KPS, Karnofsky Performance Status; TBI, total body irradiation.

^*Data missing on 65 patients in registry.